Shares of Sangamo Therapeutics Inc. (SGMO) are currently trading at $10.00, up 30 cents or 3.09% Wednesday morning. The stock has been trading in the range of $4.81 - $13.20 for the past one year, with trading volume of over 315K versus an average volume of 1.62 million shares.
Sangamo Therapeutics and Pfizer Inc. (PFE) announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.
AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.